A New Zealand platform to enable genetic investigation of adverse drug reactions.
In conclusion, we have developed a programme for studying the genetic basis of severe, rare or unusual ADR cases resulting from pharmacological treatment. Genomic analyses could eventually identify most genetic variants that predispose to ADRs, enabling a priori detection of such variants with high throughput DNA tests.
PMID: 29197902 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
More News: Drugs & Pharmacology | General Medicine | Genetics | New Zealand Health | Study | Toxicology